Pfizer (NYSE:PFE) officially debuted its discount program on the TrumpRx platform Thursday, offering more than 30 branded medicines at steep price cuts as part of its "Most Favored Nation" (MFN) pact with the White House.
The New York-based pharmaceutical giant is the first to operationalize the voluntary agreement struck in late 2025, which aims to align U.S. drug prices with the lower rates found in other wealthy nations.
Under the new program, patients paying cash—including the uninsured and those choosing to bypass their insurance—can access savings averaging 50%, with some treatments for migraines, rheumatoid arthritis, and atopic dermatitis discounted by as much as 85%.
The launch marks a pivotal moment in the Trump administration’s effort to end "global freeloading," where higher U.S. prices have historically subsidized lower costs abroad.
"For far too long, Americans have shouldered a disproportionate share of the global cost of innovation," CEO Albert Bourla stated, emphasizing that the deal protects Pfizer’s R&D capabilities while providing immediate relief to over 100 million potential patients.
To facilitate the rollout, Pfizer has integrated its pricing with GoodRx, allowing patients to use digital coupons at nearly any U.S. pharmacy or through the PfizerForAll direct-to-consumer platform.